tacrolimus has been researched along with Castleman-Disease* in 5 studies
3 review(s) available for tacrolimus and Castleman-Disease
Article | Year |
---|---|
Multicentric Castleman's disease in a renal allograft recipient: a case report and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Castleman Disease; Cyclophosphamide; Doxorubicin; Humans; Immunoglobulins; Immunosuppressive Agents; Kidney; Kidney Failure, Chronic; Kidney Transplantation; Lymph Nodes; Male; Mycophenolic Acid; Prednisone; Tacrolimus; Transplantation, Homologous; Treatment Outcome; Vincristine | 2020 |
Successful treatment with tacrolimus in TAFRO syndrome: two case reports and literature review.
TAFRO syndrome is a systemic inflammatory disorder characterized by thrombocytopenia, anasarca, fever, reticulin fibrosis, renal dysfunction, and organomegaly. In contrast to that in multicentric Castleman disease, interleukin-6 targeting strategies seem ineffective in some TAFRO syndrome cases; however, the optimal treatment remains unclear. Here, we report 2 cases of TAFRO syndrome, where 1 with cardiomyopathy, successfully treated with tacrolimus. This is the first case report of successful treatment with tacrolimus in TAFRO syndrome.. Both patients (cases 1 and 2) developed fever, anasarca, thrombocytopenia, renal dysfunction, and mild hepatosplenomegaly.. In both patients, lymph node pathology revealed mixed type Castleman disease-like features, and bone marrow showed reticulin myelofibrosis. TAFRO syndrome was diagnosed based on the patients' laboratory, clinical, and pathologic findings. In case 2, we observed a rare complication of cardiomyopathy with no evidence of takotsubo cardiomyopathy or viral myocarditis.. In case 1, tocilizumab combined with glucocorticoids was ineffective and caused septic shock; additionally, cyclosporine A was discontinued because of hepatotoxicity. However, tacrolimus was effective in resolving TAFRO syndrome without any adverse events. In case 2, tacrolimus completely reversed TAFRO syndrome and was also effective in cardiomyopathy.. This report suggests that tacrolimus is potentially effective and safe as an initial treatment and a glucocorticoid-sparing agent. Our literature review shows that calcineurin inhibitors, including tacrolimus, may be effective in TAFRO syndrome. Since previous studies indicate a role of Th1 inflammation in TAFRO syndrome pathogenesis, tacrolimus may, therefore, be effective in treating TAFRO syndrome. Topics: Adolescent; Aged; Bone Marrow; Calcineurin Inhibitors; Cardiomyopathies; Castleman Disease; Cyclosporine; Edema; Female; Fever; Fibrosis; Glucocorticoids; Hepatomegaly; Humans; Interleukin-6; Male; Primary Myelofibrosis; Renal Insufficiency; Splenomegaly; Syndrome; Tacrolimus; Thrombocytopenia; Treatment Outcome | 2018 |
Castleman disease in a pediatric liver transplant recipient: a case report and literature review.
Castleman disease is a rare hematologic disorder, closely linked to the HHV-8, and most commonly observed in immunocompromised individuals. Thirteen months following a liver transplant for CPS-1 defect, a 15-month-old boy presented with fevers, anemia, and growth retardation. Abdominal CT scan showed splenomegaly and generalized lymphadenopathy. Histology of chest wall lymph nodes revealed a mixed CD3+ T-cell and CD20+ B-cell population with atretic germinal centers consistent with multicentric Castleman disease. Qualitative DNA PCR detected HHV-8 in the resected lymph node and in the blood, supporting the diagnosis. Immunosuppression was tapered, and he was transitioned from tacrolimus to sirolimus. His graft function remained stable, and repeat imaging showed regression of the lymphadenopathy. The child is living one yr after Castleman disease diagnosis with a well-functioning graft. Castleman disease is a potential complication of solid organ transplant and HHV-8 infection. Reduction in immunosuppression and switch to sirolimus may be an effective strategy to treat this condition. Topics: Adolescent; Adult; Antigens, CD20; B-Lymphocytes; Castleman Disease; CD3 Complex; Graft Survival; Herpesvirus 8, Human; Humans; Immunosuppressive Agents; Infant, Newborn; Liver Failure; Liver Transplantation; Lymphatic Diseases; Male; Middle Aged; Polymerase Chain Reaction; Sirolimus; Splenomegaly; T-Lymphocytes; Tacrolimus; Tomography, X-Ray Computed | 2012 |
2 other study(ies) available for tacrolimus and Castleman-Disease
Article | Year |
---|---|
Disseminated Mycobacterium mantenii infection with multiple purulent cutaneous lesions.
Topics: Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Castleman Disease; Disease Progression; Humans; Immunosuppressive Agents; Male; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Prednisolone; Skin Diseases, Bacterial; Tacrolimus | 2015 |
A case of multicentric Castleman's disease having lung lesion successfully treated with humanized anti-interleukin-6 receptor antibody, tocilizumab.
This report presents the case of a patient demonstrating multicentric Castleman's disease (MCD) with a lung lesion that was successfully treated with an anti-interleukin-6 receptor antibody, tocilizumab in combination with corticosteroid and tacrolimus. A 43-yr-old female with abnormal shadows on a chest X-ray was referred to the hospital for further examination. She was diagnosed as having MCD based on the characteristic pathology of inguinal lymph node, lung lesions, laboratory data, and undifferentiated arthritis. Corticosteroid and rituximab therapy did not fully ameliorate the symptoms; thus, the therapeutic regimen was changed to include tocilizumab, oral corticosteroid and tacrolimus. This regimen resulted in clinical remission and the dose of tocilizumab and corticosteroid could be tapered. Tocilizumab in combination with corticosteroid and tacrolimus may therefore be a beneficial treatment regimen for lung lesions associated with MCD. Topics: Adrenal Cortex Hormones; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Castleman Disease; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Lung Diseases, Interstitial; Lymph Nodes; Receptors, Interleukin-6; Tacrolimus; Tomography, X-Ray Computed | 2010 |